Top

Published in:

Open Access 01-12-2022 | Care | Research

Facilitators for retaining men who have sex with men in pre-exposure prophylaxis care in real world clinic settings within the United States

Authors: Brooke G. Rogers, C. Sosnowy, A. Zanowick-Marr, P. A. Chan, L. A. Mena, R. R. Patel, W. C. Goedel, T. Arnold, C. Chu, D. Galipeau, M. C. Montgomery, K. Curoe, A. Underwood, J. Villalobos, C. Gomillia, A. S. Nunn

Published in: BMC Infectious Diseases | Issue 1/2022

Abstract

Background

Pre-exposure prophylaxis (PrEP) can significantly reduce HIV acquisition especially among communities with high HIV prevalence, including men who have sex with men (MSM). Much research has been finding suboptimal PrEP persistence; however, few studies examine factors that enhance PrEP persistence in real-world settings.

Methods

We interviewed 33 patients who identified as MSM at three different PrEP clinics in three regions of the U.S. (Northeast, South, Midwest). Participants were eligible if they took PrEP and had been retained in care for a minimum of 6 months. Interviews explored social, structural, clinic-level and behavioral factors that influencing PrEP persistence.

Results

Through thematic analysis we identified the following factors as promoting PrEP persistence: (1) navigation to reduce out-of-pocket costs of PrEP (structural), (2) social norms that support PrEP use (social), (3) access to LGBTQ + affirming medical providers (clinical), (4) medication as part of a daily routine (behavioral), and (5) facilitation of sexual health agency (belief).

Discussion

In this sample, persistence in PrEP care was associated with structural and social supports as well as a high level of perceived internal control over protecting their health by taking PrEP. Patients might benefit from increased access, LGBTQ + affirming medical providers, and communications that emphasize PrEP can promote sexual health.

Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34. https://doi.org/10.1056/NEJMoa1110711.CrossRefPubMed

Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99. https://doi.org/10.1056/NEJMoa1011205.CrossRefPubMedPubMedCentral

Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9. https://doi.org/10.1016/S1473-3099(14)70847-3.CrossRefPubMedPubMedCentral

Baeten JM, Celum C. Antiretroviral preexposure prophylaxis for HIV prevention. N Engl J Med. 2013;368(1):83–4. https://doi.org/10.1056/NEJMc1210464.CrossRefPubMed

HIV Surveillance Report, 2017; Vol 29. Centers for Disease Control and Prevention. 2018. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Accessed November 10, 2019.

King HL, Keller SB, Giancola MA, et al. Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE Study). AIDS Behav. 2014;18(9):1722–5. https://doi.org/10.1007/s10461-014-0845-5.CrossRefPubMedPubMedCentral

Krakower DS, Mimiaga MJ, Rosenberger JG, et al. Limited awareness and low immediate uptake of pre-exposure prophylaxis among men who have sex with men using an internet social networking site. PLoS ONE. 2012;7(3): e33119. https://doi.org/10.1371/journal.pone.0033119.CrossRefPubMedPubMedCentral

Chan PA, Mena L, Patel R, et al. Retention in care outcomes for HIV pre-exposure prophylaxis implementation programmes among men who have sex with men in three US cities. J Int AIDS Soc. 2016;19(1):20903. https://doi.org/10.7448/IAS.19.1.20903.CrossRefPubMedPubMedCentral

Chan PA, Patel RR, Mena L, et al. Long-term retention in pre-exposure prophylaxis care among men who have sex with men and transgender women in the United States. J Int AIDS Soc. 2019;22(8): e25385. https://doi.org/10.1002/jia2.25385.CrossRefPubMedPubMedCentral

10.

Hojilla JC, Vlahov D, Crouch PC, Dawson-Rose C, Freeborn K, Carrico A. HIV pre-exposure prophylaxis (PrEP) uptake and retention among men who have sex with men in a community-based sexual health clinic. AIDS Behav. 2018;22(4):1096–9. https://doi.org/10.1007/s10461-017-2009-x.CrossRefPubMedPubMedCentral

11.

Coy KC, Hazen RJ, Kirkham HS, Delpino A, Siegler AJ. Persistence on HIV preexposure prophylaxis medication over a 2-year period among a national sample of 7148 PrEP users, United States, 2015 to 2017. J Int AIDS Soc. 2019;22(2): e25252. https://doi.org/10.1002/jia2.25252.CrossRefPubMedPubMedCentral

12.

Spinelli MA, Buchbinder SP. Pre-exposure prophylaxis persistence is a critical issue in PrEP implementation. Clin Infect Dis. 2020;71(3):583–5. https://doi.org/10.1093/cid/ciz896.CrossRefPubMed

13.

Young I, Flowers P, McDaid LM. Barriers to uptake and use of pre-exposure prophylaxis (PrEP) among communities most affected by HIV in the UK: findings from a qualitative study in Scotland. BMJ Open. 2014;4(11): e005717. https://doi.org/10.1136/bmjopen-2014-005717.CrossRefPubMedPubMedCentral

14.

Ezennia O, Geter A, Smith DK. The PrEP care continuum and black men who have sex with men: a scoping review of published data on awareness, uptake, adherence, and retention in PrEP care. AIDS Behav. 2019;23(10):2654–73. https://doi.org/10.1007/s10461-019-02641-2.CrossRefPubMed

15.

Dubov A, Galbo P, Altice FL, Fraenkel L. Stigma and shame experiences by MSM who take PrEP for HIV prevention: a qualitative study. Am J Mens Health. 2018;12(6):1843–54. https://doi.org/10.1177/1557988318797437.CrossRefPubMedPubMedCentral

16.

Arnold T, Brinkley-Rubinstein L, Chan PA, et al. Social, structural, behavioral and clinical factors influencing retention in pre-exposure prophylaxis (PrEP) care in Mississippi. PLoS ONE. 2017;12(2): e0172354. https://doi.org/10.1371/journal.pone.0172354.CrossRefPubMedPubMedCentral

17.

Storholm ED, Volk JE, Marcus JL, Silverberg MJ, Satre DD. Risk perception, sexual behaviors, and PrEP adherence among substance-using men who have sex with men: a qualitative study. Prev Sci. 2017;18(6):737–47. https://doi.org/10.1007/s11121-017-0799-8.CrossRefPubMedPubMedCentral

18.

Gilmore HJ, Liu A, Koester KA, et al. Participant experiences and facilitators and barriers to pill use among men who have sex with men in the iPrEx pre-exposure prophylaxis trial in San Francisco. AIDS Patient Care STDs. 2013;27(10):560–6. https://doi.org/10.1089/apc.2013.0116.CrossRefPubMedPubMedCentral

19.

Brooks RA, Landrian A, Nieto O, Fehrenbacher A. Experiences of anticipated and enacted pre-exposure prophylaxis (PrEP) stigma among Latino MSM in Los Angeles. AIDS Behav. 2019;23(7):1964–73. https://doi.org/10.1007/s10461-019-02397-9.CrossRefPubMedPubMedCentral

20.

Rusie LK, Orengo C, Burrell D, et al. Preexposure prophylaxis initiation and retention in care over 5 years, 2012–2017: are quarterly visits too much? Clin Infect Dis. 2018;67(2):283–7. https://doi.org/10.1093/cid/ciy160.CrossRefPubMedPubMedCentral

21.

Patel RR, Mena L, Nunn A, et al. Impact of insurance coverage on utilization of pre-exposure prophylaxis for HIV prevention. PLoS ONE. 2017;12(5): e0178737. https://doi.org/10.1371/journal.pone.0178737.CrossRefPubMedPubMedCentral

22.

Whitfield THF, John SA, Rendina HJ, Grov C, Parsons JT. Why I quit pre-exposure prophylaxis (PrEP)? A mixed-method study exploring reasons for PrEP discontinuation and potential re-initiation among gay and bisexual men. AIDS Behav. 2018;22(11):3566–75. https://doi.org/10.1007/s10461-018-2045-1.CrossRefPubMedPubMedCentral

23.

Serota DP, Rosenberg ES, Sullivan PS, et al. Pre-exposure prophylaxis uptake and discontinuation among young black men who have sex with men in Atlanta, Georgia: a prospective cohort study. Clin Infect Dis. 2020;71(3):574–82. https://doi.org/10.1093/cid/ciz894.CrossRefPubMed

24.

Wood S, Gross R, Shea JA, et al. Barriers and facilitators of PrEP adherence for young men and transgender women of color. AIDS Behav. 2019;23(10):2719–29. https://doi.org/10.1007/s10461-019-02502-y.CrossRefPubMedPubMedCentral

25.

Golub SA, Gamarel KE, Rendina HJ, Surace A, Lelutiu-Weinberger CL. From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Patient Care STDs. 2013;27(4):248–54. https://doi.org/10.1089/apc.2012.0419.CrossRefPubMedPubMedCentral

26.

Peng L, Cao W, Gu J, et al. Willingness to use and adhere to HIV pre-exposure prophylaxis (PrEP) among men who have sex with men (MSM) in China. Int J Environ Res Public Health. 2019;16(14):2620. https://doi.org/10.3390/ijerph16142620.CrossRefPubMedCentral

27.

Closson EF, Mitty JA, Malone J, Mayer KH, Mimiaga MJ. Exploring strategies for PrEP adherence and dosing preferences in the context of sexualized recreational drug use among MSM: a qualitative study. AIDS Care. 2018;30(2):191–8. https://doi.org/10.1080/09540121.2017.1360992.CrossRefPubMed

28.

Carlo Hojilla J, Koester KA, Cohen SE, et al. Sexual behavior, risk compensation, and HIV prevention strategies among participants in the San Francisco PrEP demonstration project: a qualitative analysis of counseling notes. AIDS Behav. 2016;20(7):1461–9. https://doi.org/10.1007/s10461-015-1055-5.CrossRefPubMed

29.

Punchihewa T, Saxton P, Wiles J. “The promise of PrEP”: motivations for taking PrEP among early-adopting New Zealand gay and bisexual men. Sex Transm Infect. 2019;95(Suppl 1):A201.

30.

Collins SP, McMahan VM, Stekler JD. The impact of HIV pre-exposure prophylaxis (PrEP) use on the sexual health of men who have sex with men: a qualitative study in Seattle, WA. Int J Sex Health. 2017;29(1):55–68. https://doi.org/10.1080/19317611.2016.1206051.CrossRef

31.

Hennink MM, Kaiser BN, Marconi VC. Code saturation versus meaning saturation: how many interviews are enough? Qual Health Res. 2017;27(4):591–608. https://doi.org/10.1177/1049732316665344.CrossRefPubMed

32.

Thomas DR. A general inductive approach for analyzing qualitative evaluation data. Am J Eval. 2006;27(2):237–46. https://doi.org/10.1177/1098214005283748.CrossRef

33.

Golub SA, Fikslin RA, Goldberg MH, Peña SM, Radix A. Predictors of PrEP uptake among patients with equivalent access. AIDS Behav. 2019;23(7):1917–24. https://doi.org/10.1007/s10461-018-2376-y.CrossRefPubMedPubMedCentral

34.

D’Angelo AB, Lopez-Rios J, Flynn AWP, Holloway IW, Pantalone DW, Grov C. Insurance- and medical provider-related barriers and facilitators to staying on PrEP: results from a qualitative study. Transl Behav Med. 2021;11(2):573–81. https://doi.org/10.1093/tbm/ibz191.CrossRefPubMed

35.

Mayer KH, Agwu A, Malebranche D. Barriers to the wider use of pre-exposure prophylaxis in the United States: a narrative review. Adv Ther. 2020;37(5):1778–811. https://doi.org/10.1007/s12325-020-01295-0.CrossRefPubMedPubMedCentral

36.

Kay ES, Pinto RM. Is insurance a barrier to HIV preexposure prophylaxis? Clarifying the issue. Am J Public Health. 2020;110(1):61–4. https://doi.org/10.2105/AJPH.2019.305389.CrossRefPubMedPubMedCentral

37.

Adamson B, Lipira L, Katz AB. The impact of ACA and medicaid expansion on progress toward UNAIDS 90–90-90 goals. Curr HIV/AIDS Rep. 2019;16(1):105–12. https://doi.org/10.1007/s11904-019-00429-6.CrossRefPubMed

38.

Keith K. New guidance on PrEP: support services must be covered without cost-sharing. Following the ACA. Published July 28, 2021. https://www.healthaffairs.org. doi: https://doi.org/10.1377/hblog20210728.333084. Accessed Nov 8, 2021.

39.

Rolle CP, Rosenberg ES, Siegler AJ, et al. Challenges in translating PrEP interest into uptake in an observational study of young black MSM. J Acquir Immune Defic Syndr 1999. 2017;76(3):250–8. https://doi.org/10.1097/QAI.0000000000001497.CrossRef

40.

Need for financial assistance for PrEP in USA. PharmacoEcon Outcomes News. 2017;786(1):26–26. https://doi.org/10.1007/s40274-017-4316-x.CrossRef

41.

Calabrese SK, Mayer KH. Stigma impedes HIV prevention by stifling patient-provider communication about U = U. J Int AIDS Soc. 2020;23(7): e25559. https://doi.org/10.1002/jia2.25559.CrossRefPubMedPubMedCentral

42.

Zapata JP, Petroll A, Aubin EDS, Quinn K. Perspectives on social support and stigma in PrEP-related care among gay and bisexual men: a qualitative investigation. J Homosex. 2020. https://doi.org/10.1080/00918369.2020.1819709.CrossRefPubMed

43.

Frost DM, Meyer IH, Schwartz S. Social support networks among diverse sexual minority populations. Am J Orthopsychiatry. 2016;86(1):91–102. https://doi.org/10.1037/ort0000117.CrossRefPubMedPubMedCentral

44.

Burton CL, Bonanno GA, Hatzenbuehler ML. Familial social support predicts a reduced cortisol response to stress in sexual minority young adults. Psychoneuroendocrinology. 2014;47:241–5. https://doi.org/10.1016/j.psyneuen.2014.05.013.CrossRefPubMedPubMedCentral

45.

Safren SA, Gonzalez JS, Soroudi N. Coping with chronic illness: a cognitive-behavioral therapy approach for adherence and depression: therapist guide. Oxford: Oxford University Press; 2008.

46.

Strecher VJ, DeVellis BM, Becker MH, Rosenstock IM. The role of self-efficacy in achieving health behavior change. Health Educ Q. 1986;13(1):73–92. https://doi.org/10.1177/109019818601300108.CrossRefPubMed

47.

Teng Y, Mak WWS. The role of planning and self-efficacy in condom use among men who have sex with men: an application of the Health Action Process Approach model. Health Psychol. 2011;30(1):119–28. https://doi.org/10.1037/a0022023.CrossRefPubMed

48.

Safren SA, Blashill AJ, Lee JS, et al. Condom-use self-efficacy as a mediator between syndemics and condomless sex in men who have sex with men (MSM). Health Psychol. 2018;37(9):820–7. https://doi.org/10.1037/hea0000617.CrossRefPubMedPubMedCentral

49.

Calabrese SK, Underhill K. How stigma surrounding the use of HIV preexposure prophylaxis undermines prevention and pleasure: a call to destigmatize “truvada whores.” Am J Public Health. 2015;105(10):1960–4. https://doi.org/10.2105/AJPH.2015.302816.CrossRefPubMedPubMedCentral

50.

Marcus JL, Glidden DV, Mayer KH, et al. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis. PLoS ONE. 2013;8(12): e81997. https://doi.org/10.1371/journal.pone.0081997.CrossRefPubMedPubMedCentral

51.

Harkness A, Rogers BG, Balise R, et al. Who aren’t we reaching? Young sexual minority men’s non-participation in an HIV-prevention and mental health clinical trial. AIDS Behav. 2021;25(7):2195–209. https://doi.org/10.1007/s10461-020-03148-x.CrossRefPubMedPubMedCentral

Title: Facilitators for retaining men who have sex with men in pre-exposure prophylaxis care in real world clinic settings within the United States
Authors: Brooke G. Rogers
C. Sosnowy
A. Zanowick-Marr
P. A. Chan
L. A. Mena
R. R. Patel
W. C. Goedel
T. Arnold
C. Chu
D. Galipeau
M. C. Montgomery
K. Curoe
A. Underwood
J. Villalobos
C. Gomillia
A. S. Nunn
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Care
Human Immunodeficiency Virus
Published in: BMC Infectious Diseases / Issue 1/2022
Electronic ISSN: 1471-2334
DOI: https://doi.org/10.1186/s12879-022-07658-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Facilitators for retaining men who have sex with men in pre-exposure prophylaxis care in real world clinic settings within the United States

Abstract

Background

Methods

Results

Discussion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Discussion

Please log in to get access to this content

Other articles of this Issue 1/2022

A case report of Klebsiella aerogenes-caused lumbar spine infection identified by metagenome next-generation sequencing

Risk-prone territories for spreading tuberculosis, temporal trends and their determinants in a high burden city from São Paulo State, Brazil

Similar severity of influenza primary and re-infections in pre-school children requiring outpatient treatment due to febrile acute respiratory illness: prospective, multicentre surveillance study (2013–2015)

Seroprevalence of SARS-CoV-2 antibodies among children and adolescents recruited in a malariometric survey in north-eastern Tanzania July 2021

Risk factors for healthcare-associated infection among children in a low-and middle-income country

Effect of different interventions for latent tuberculosis infections in China: a model-based study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page